(NASDAQ: TPST) Tempest Therapeutics's forecast annual earnings growth rate of N/A is not forecast to beat the US Biotechnology industry's average forecast earnings growth rate of 136.1%, and while it is not forecast to beat the US market's average forecast earnings growth rate of 102.13%.
Tempest Therapeutics's earnings in 2026 is -$36,054,000.On average, 3 Wall Street analysts forecast TPST's earnings for 2026 to be -$72,554,007, with the lowest TPST earnings forecast at -$69,708,752, and the highest TPST earnings forecast at -$74,687,948. On average, 3 Wall Street analysts forecast TPST's earnings for 2027 to be -$60,371,093, with the lowest TPST earnings forecast at -$58,003,599, and the highest TPST earnings forecast at -$62,146,713.
In 2028, TPST is forecast to generate -$71,965,241 in earnings, with the lowest earnings forecast at -$69,143,075 and the highest earnings forecast at -$74,081,866.